Gemina Labs has developed and patented a transformative bio-chemistry that powers next-generation testing platforms for detecting a wide range of pathogens that affect humans and animals. Our tests are fast, affordable and accurate, and easily self-administered providing consumers with direct solutions where they need them.
The Gemina Labs dual affinity probe technology establishes a flexible and novel approach to attaching functional biomolecules to diverse surfaces …The technology has been evaluated by Paragreen and offers significant potential competitive advantages including increased performance and cost efficiency in applications ranging from human and veterinary diagnostics to environmental testing, food safety, agriculture, and industrial bioprocessing.”
We're building a new category of biosensors - moving diagnosis out of the clinic and into the hands of the patient and user...
Gemina’s team is comprised of industry-leading experts in the research, development, and commercialization of biotechnologies.
Over 25 years experience and over 100 IP commercializations in Europe and Canada. Founding member of LSE listed IP Group (LON:IPO), former CEO of Scientific Research Capital. Trained in law at Oxford University, and qualified as an accountant in the UK.
Scientific founder and lead researcher, with 20 years of commercial and laboratory research in surface chemistry applications in medical technology and mining. Master's in Chemistry from UBC.
Original training in Pharmaceutical Sciences in addition to Chartered Accountant designation. Spent 7 years with Price Waterhouse Coopers, and has accumulated more than 20 years experience in public company CFO roles.
Highly experienced research and commercial scientist with a PhD in molecular biology and immunology from University of Zurich. 14 years of commercial experience in biotechnology companies.
Serial entrepreneur, building on a PhD in Management Information Systems and the University of Washington. Appointed as Research Fellow at UBC’s Urban Data Lab.
Senior scientist and product developer with over 40 years of experience in life science product management with companies including Phillips, Kodak Clinical Products, J&J Diagnostics and IGEN.
Highly experienced business development professional. Former VP Innovation with Stuart Olson building on BD roles with AMP, IBM, PURUS.
Experienced entrepreneur and professor at the Sauder School of Business. Founder of Centre for Social Innovation and Impact Investing and CEO of Canvas Impact Advisors. Global authority on impact investing and active in the Creative Destruction Lab.
Scientific founder and lead researcher, with 20 years of commercial and laboratory research in surface chemistry applications in medical technology and mining. Master's in Chemistry from UBC.
Over 25 years experience and over 100 IP commercializations in Europe and Canada. Founding member of LSE listed IP Group (LON:IPO), former CEO of Scientific Research Capital. Trained in law at Oxford University, and qualified as an accountant in the UK.
-min.png)
Senior executive with over 20 years experience in international diplomacy with the British Government. Extensive international relationships at corporate and government levels. Served as CEO and Director of companies including Patriot One (TSX:PAT) and Helios Global.
More than 20 years experience in capital markets and business development across multiple sectors. Experience in due diligence, local and cross-border mergers, corporate acquisitions, and compliance issues, having worked with companies in multiple jurisdictions including those publicly trading in Canada, the United States, and Germany.
Professor and Turing Fellow, Newcastle University. Career in vitro diagnostic product development (Swiss Precision, Unilever) including pioneering the development of the Clearblue lateral flow assay pregnancy test. At Unilever he led the Healthy Aging program for integrated technologies for lifestyle interventions.
Early career as a biotech analyst, launched career as an executive and board positions in biotechnology companies in Canada and the US. Responsible for commercial transactions with Alexion Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, and JDR.
Executive with thirty years experience in Fortune 100 companies in the development of life science technologies. Worked in product development with Amersham, Kodak Diagnostics, Boehringer Mannheim and others. Background includes extensive experience in clinical diagnostics, therapeutics and diagnostic imaging.
.svg)
